(1) Clinical utility of the pathogenesis-related proteins in Alzheimer’s disease

(2) Authors:

Bin Zhou, MD, PhD1, Masanori Fukushima, MD, PhD1,

Address: 1. Translational Research Informatics Center

Foundation for Biomedical Research and Innovation

Kobe, Japan

(3) Corresponding:

Bin Zhou, M.D., PhD

1-5-4 Minatojima-minamimachi, Chuo-ku

Translational Research Informatics Center

Foundation for Biomedical Research and Innovation

Kobe, 650-0047, Japan

Phone: +81-78-3039093, Fax: +81-78-3039094

Email: zhoubin@tri-kobe.org

© 2020 by the author(s). Distributed under a Creative Commons CC BY license.
Clinical utility of the pathogenesis-related proteins in Alzheimer’s disease

Abstract
The Aβ cascade and alternations of biomarkers in neuro-inflammation, synaptic dysfunction and neuronal injury followed by Aβ have progressed. But the question is how to use the biomarkers. Here, we examine the evidence and pathogenic implications of protein interactions and the time order of alternation. After the deposition of Aβ, the change of tau, NfL and NG is the main alternation and connection to others. The neuro-inflammation, synaptic dysfunction and neuronal injury function is exhibited prior the structural and metabolic changes in the brain following Aβ deposition. The time order of such biomarkers compared to the tau protein is not clear. Despite the close relationship between biomarkers and plaque Aβ deposition, several factors favor one or the other. There is an interaction between the proteins that CSF SNAP-25, VILIP-1 and YKL-40 can predict the brain amyloid burden. The Aβ cascade hypothesis could be the pathway, but not all subjects are converted to AD, even with very high elevated Aβ. The interaction of biomarkers and the time order of change require further research to identify the right subjects and right molecular target for precision medicine therapies.

Keyword: Alzheimer’s disease, biomarkers dynamics, interaction, time order
Introduction

The amyloid hypothesis of Alzheimer’s disease (AD) proposes that accumulation of amyloid-beta (Aβ) in the brain triggers pathogenesis of AD and the cascade of the spread of tau-related neurofibrillary tangles, neuro-inflammation, and neuronal degeneration. The failure of the anti-Aβ clinical trials indicated that the therapeutic potential of BACE-1 inhibition and anti-amyloid antibody is doubling [1-4]. The question on the amyloid hypothesis of Alzheimer’s disease has been raised in recent years.

However, much evidence still confirms that the Aβ appears to be the initial disease mechanism in AD. Among initially amyloid-negative adults, Farrell found a regionally specific association between declining episodic memory and increased amyloid accumulation across multiple posterior cortical regions [5-6].

In the event of failure of clinical trials, Knopman[1] considered the selection of a population with positive Aβ to be too late for maximum treatment effect. Bischof[7] and Palmqvist[6] have proposed a potential solution for enrolling subjects with threshold amyloidosis. From experience, defining the threshold is very difficult. Higher SUVR of Aβ does not always indicate the late AD stage. At the same level of Aβ PET, higher FDG-PET reduces the risk of AD in MCI or Normal subjects. Even in the subjects with very high SUVR of Aβ, the modulation of higher FDG-PET continues to reduce the risk of conversion to AD (zhou, unpublished).
Many studies have shown that in the downstream of Aβ, proteins have changed the spread of tau-related neurofibrillary tangles, synaptic dysfunction, neuro-inflammation, neuronal injury and neuronal degeneration all of which are associated with the pathogenesis of AD. However the interaction and the time order of changes of the proteins are not clear yet, which makes it difficult to clarify the molecular pathway. Palmqvist [6] proposed one order of the biomarkers based on the accumulation of Aβ PET in a cross-sectional data that could not reflect the time order. As noted by the author, it requires the follow-up of Aβ PET and the rates of change of Aβ.

In the hypothesis of AD pathogenesis proposed by Jack CR [8], the change of MRI and PDG-PET is accompanied by the accumulation of Aβ. Some studies showed that accumulation of Aβ resulted in hippocampal atrophy. However, the deposition of Aβ does not imply that the hippocampus is definitely atrophy. Aβ pathology and hippocampal atrophy are independently associated with memory function in cognitively healthy elderly people [9]. In the prediction analysis, MCI or normal cognition subjects with positive Aβ and hippocampal atrophy increased the risk of transition to AD. We also observed that not all subjects with elevated Aβ have hippocampal atrophy. The change in glucose metabolism measured by FDG-PET showed similar results. The involvement of structural MRI and glucose metabolism measured by FDG-PET with the pathogenesis of AD can be independent of Aβ. Successful treatment strategies can be devised by understanding the contribution of these markers to different aspects of disease pathogenesis.
The framework of amyloid (A), tau (T), and neuro-degeneration (N) biomarkers is proposed to define the state of patients with regard to Alzheimer pathologic change. The group with abnormal levels of amyloid, tau, and neuro-degeneration (A+T+N+) showed consistently greater cognitive decline than the group with normal levels of all biomarkers (A-T-N-)[10]. The ATN system has different implications in patients with vs without dementia that it poses a challenge to discriminate between patient populations with specific features [11] and clinical trial design. Timing is always the challenge for subjects enrollment in AD clinical trials [1,12]. Before we figure out the pathway that includes pathological molecular changes and related association, we cannot make a clear definition of the timing. Based on the published results, efforts shall be made to clarify the interactions and time order of the proteins’ change in order to set up the pathway of AD pathogenesis, as shown in Figure 1.

1. The change of biomarkers in Alzheimer’s Disease

1.1 Aβ and tau

Researches indicated that CSF Aβ decreased while Brain PET Aβ increased in AD when compared with CN. CSF t-Tau and CSF p-tau increased at an early stage of the AD time pathogenesis compared to mild cognitive impairment (MCI) and normal cognition group [13-15]. Longitudinally, CSF Aβ decreased in all groups, however t-tau and p-tau levels increased significantly in the CN+ or CN group, while it decreased in the AD+ or AD group [13-14].
1.2 Synaptic dysfunction

Synaptic dysfunction and degeneration are early fundamental pathophysiological characteristics of AD. Biomarkers that can track synaptic dysfunction in AD are eagerly awaited.

The major proteins of synaptic dysfunction involved in the pathogenesis of AD are neurogranin, SNAP-25, synaptotagmin, syntaxin and Ca2+ complexin-1, complexin-2.

CSF Ng was increased in AD compared to CN or Parkinson's disease frontotemporal dementia and amyotrophic lateral sclerosis [15-17]. Baseline levels of Ng were significantly higher in the AD+ group than the CN and MCI− groups. The levels were also higher in the MCI+ group compared to the Aβ- (CN and MCI) groups. Longitudinally, CSF Ng or Brain Ng significantly decreased in the AD+ group or AD patients [13-14]. Ng/BACE1 levels were elevated in both subjective cognitive decline and mild cognitive impairment compared to healthy controls [18], and can distinguish between depression and AD among patients with similar cognitive deficits, along with the classic AD biomarkers [19].

SNAP25 increased in AD or MCI versus CN [12,15]. However Beeri [20] and Shimohama [21] indicated dementia to be associated with reductions in SNAP-25. Longitudinally, SNAP-25 levels declined significantly in the AD+ group, which indicates the varying level of SNAP25 at different stages of AD.
In AD, the levels of synaptobrevin and synaptophysin decreased significantly from the levels of control. Other synaptic factors of synaptotagmin, and syntaxin 1/HPC-1, complexin-1, complexin-2 and septin-5 have also been reported to decrease [20-21].

1.3 Neuro-inflammation

The inflammation associated proteins include microglial function, TREM2, YKL-40, IP-10, complement C etc. Chitinase-3-like protein 1 (CHI3L1), also known as YKL-40, is a secreted glycoprotein that is approximately 40kDa in size and is encoded by the CHI3L1 gene in humans. Elevated concentrations of YKL-40, VILIP-1 and sTREM2 in CSF were observed in MCI when compared with the control [22]. Baseline YKL-40 was significantly higher in the AD+ when compared with the MCI−. Longitudinally, YKL-40 in all Aβ+ and Aβ- groups of AD, MCI, and CN showed an increase in mean levels over time [13]

Using post-mortem human, Singh-Bains [23] demonstrated that there was 91% and 69% increase in the expression and load of IBA1(microglia) , respectively; the process length and branching of HLA-DR(microglia) positive cell was reduced by 33% and 49%, respectively; there was a 27% increase in the Astrocytes (GFAP) basement-membrane associated molecules Fibronectin expression in AD. Microglial and neurovascular dysfunction act as drivers of AD. In the case of TREM2, Plasma sTREM2
does not differ between healthy controls, mild cognitive impairment (MCI) or AD. [24]

1.4 Neuronal injury
Cerebrospinal fluid (CSF) neuro-filament light (NFL) is a protein biomarker of axonal injury. Visinin-like protein 1 is a protein encoded by the VSNL1 gene in humans. This gene is a member of the visinin/recoverin subfamily of neuronal calcium sensor proteins. NF-L and VILIP-1 of neuronal injury have been reported to predict more FTD disease progression than AD.

Synaptic damage, axonal neuro-degeneration, and neuro-inflammation are common features in Alzheimer's disease (AD), frontotemporal dementia (FTD), and Creutzfeldt-Jakob disease (CJD). Although there was a stepwise increase in CSF NFL levels between control participants, participants with MCI, and Alzheimer disease; however the concentrations of NFL were highest in participants with amyotrophic lateral sclerosis and frontotemporal dementia (FTD)[25]. Researches indicated Neuronal injury related biomarkers of YKL-40 and NfL are valuable tools for staging and predicting patients within the ALS-FTD clinical spectrum [26], or as a disease progression biomarker in genetic frontotemporal dementia [27-28] or in distinguishing behavioral variant frontotemporal dementia (bvFTD) from primary psychiatric disorders (PSY) [29].

cNfL has the potential to assist in the differentiation of FTD from AD and
PD from atypical parkinsonian syndromes [30]. NFL is not a specific biomarker for the diagnosis or progression of AD.

Mavroudis indicated that VILIP-1 levels are significantly higher in AD compared to normal controls, and these levels are significantly higher in patients with MCI progressed to AD, than in stable MCI patients in a meta-analysis [31]. As CSF VILIP-1 is an unspecific marker for neuronal injury and CSF myelin basic protein reflects neuroaxonal, the results of longer periods of stress associated with higher levels of CSF VILIP-1 suggested that long term stress may be associated with neurodegenerative processes in the brain [32].

The correlations between microglial activation with tau or amyloid deposition were stronger in Alzheimer's disease than in mild cognitive impairment, suggesting that these pathologies increase together as the disease progresses [33].

2. The interaction between the proteins and association with neuroimaging findings

2.1 Interaction between the proteins

Based on the Aβ cascade hypothesis, the deposition of Aβ resulted in the change of the biomarkers. Beyond the levels of individual proteins, protein-
protein interactions that are critical to the process of vesicular neurotransmission also contribute [34]. Identifying protein interactions may make it easier to understand the pathogenesis and early prevention of AD.

55% of MCI and 83% of AD subjects had a high Aβ load [36]. NFL and YKL-40 were associated with Aβ+ in non-demented individuals only [37]. CSF YKL-40 was positively associated with both CSF NFL and T-Tau [38]. Jin M [39] reported that CSF NFL levels correlated with total tau, phosphorylated tau, and neurogranin but not with beta amyloid (Aβ).

Baseline CSF t-Tau levels were significantly elevated in the AD+ group when compared with Aβ+(MCI CN) and Aβ-(MCI and CN) groups. Longitudinally, t-Tau levels significantly increased in both the CN and MCI+ groups, but decreased in the AD+ group. VILIP-1, SNAP-25 increased significantly with Aβ in the Aβ+ of MCI and AD when compared with Aβ- groups [13].

For the association of inflammation with Aβ, microglial activation is positively associated with tau aggregation in MCI and AD, while negatively associated with amyloid deposition [33]. Levels of Aβ and inflammation (11C-(R)-PK11195) can be seen related in MCI. There was no detected association between Cortical tau tangles and inflammation in high amyloid-β cases [36].

There was difference in Ng and T-tau between Aβ+ and Aβ- individuals in each clinical group [37]. In brain tissue from patients with familial and sporadic
Alzheimer's disease, Ng was significantly associated with the degree of amyloid and tau pathology [40]. Higher levels of SNAP-25-syntaxin interaction (controlled for the level of SNAP-25 as well as for pathology) were associated with lower likelihood of dementia. An association between SNARE complex formation and cognitive function that is in part regionally specific, and may be more prominent for specific cognitive domains [34].

Multiple variables were differentially associated with CSF NfL and T-tau levels, but not Ng. Most associations were attenuated after adjustment for age and sex. T-tau had the strongest association with cognition in the presence of amyloidosis; followed by Ng. Variables associations with NfL did not differ by amyloid status [38].

Although there is inconsistency in the results, majority of the results indicated that for biomarkers of t-Tau, P-tau, VILIP-1, SNAP-25, Ng, NFL, YKL-40 and inflammation (11C-(R)-PK11195), microglial activation began to change after the deposition of Aβ. NFL is also reported to be correlated with total tau independent of Aβ. The data of the association among other biomarker is still limited and it is difficult to identify interactions between biomarkers except for Aβ (Figure 2).

2.2 Association of the proteins with the neuroimaging findings and phenotypes
We know that change in the brain structure can be measured by MRI metabolism using FDG-PET after the deposition of Aβ in brain. However when and how the biomarkers are associated with the neuroimaging findings will be discussed in the next few paragraphs.

In amyloid-β-positive individuals, the atrophy across the entire brain is correlated with a summary measure of medial temporal lobe (MTL) 18F-AV-1451 uptake [41]. Aβ aggregation within the brain's default mode network leads to regional hypo-metabolism, and an interaction between this hypo-metabolism with overlapping Aβ aggregation is associated with subsequent cognitive decline [42].

For the synaptic biomarkers, in the temporal lobe, the trimeric SNARE protein interaction (SNAP-25, syntaxin, VAMP) was associated with the rate of cognitive decline and global cognitive function [34]. SNAP-25 genotypes also correlate with a significantly decreased brain activity in the cingulate cortex, and in the frontal and temporoparietal area [43]. Elevated SNAP-25/ Aβ42 ratio or higher Ng/BACE1 ratio was associated with the rate of hippocampal atrophy in pMCI and the rate of change of cognitive impairment in CN over the follow-up period [44-46]. A research also showed an association between longitudinal decline in white matter microstructure and change of Aβ42, phosphorylated-tau, total-tau, NFL, and neurogranin [47].

The levels of individual CSF biomarkers of visinin-like protein 1, neurogranin,
BACE1, Aβ1-40, Aβ1-38, and YKL-40 were all inversely correlated with the volume of gray matter of the precuneus in cognitively intact older subjects [48].

In inflammation, greater MCP-1, lower Aβ42, and greater P-Tau181 was associated with altered microstructure in bilateral frontal, right temporal lobe, and microstructure in precuneus, respectively [37]

Plasma and CSF NFL is cognitive in MCI [49-51] and positively with atrophy [50-51], hypometabolism, CSF biomarkers, and injury [50]. Serum Nfl is not associated with amyloid-β deposition or glucose metabolism [51]. Elevated NFL predicted white matter damage in cognitively impaired older adults who are amyloid-negative and tau-positive [52]

3. The time order of the changes of the biomarkers

The time order of some biomarkers change is as follows CSF Aβ→CSF P-tau→CSF T-tau→PET Aβ→PET tau. However we have no knowledge of when the changes occurred for other biomarkers and the time location with the MRI findings and glucose metabolism.

Only after Aβ PET became abnormal were the biomarkers of neuroinflammation, synaptic dysfunction, and neurodegeneration altered. Many findings provide in vivo support of the amyloid cascade hypotheses in humans [6]. Aβ42 caused the Cortex atrophy [13]. Brain amyloid deposition
shortly caused early change of CSF tTau, pTau, SNAP-25, VILIP-1, and YKL-40. At the same time the change of CSF SNAP-25, VILIP-1, and YKL-40 also indicated performance on a cognitive composite, brain A\(\beta\), 15-19 years before the estimated years from the onset of symptom [53]. CSF-amyloid is more sensitive early in the course of the disease.

In an animal model of AD, Ng levels increased in CSF when neurodegeneration was induced, peaking after 2 weeks, while it decreased in a brain when CSF Ng is a biomarker of synaptic degeneration [17].

The change of NfL appeared before the change of structural MRI findings and glucose metabolism measured by FDG-PET. In A\(\beta\)+ participants, NfL associates with hypo-metabolism in AD-vulnerable regions [54]. Merluzzi suggest that NFL may be more sensitive to subclinical cognitive decline compared to other proposed biomarkers for neurodegeneration, whereas neurogranin and t-tau are not [55]. The rate of change of serum NfL could distinguish mutation carriers from non-mutation carriers almost a decade earlier than cross-sectional absolute NfL levels (16.2 versus 6.8 years before the estimated onset of AD symptom) [51]. Across all mutation carriers, serum NfL correlated with EYO (estimate year of onset) and multiple cognitive and imaging measures [56].

However biomarker change is not always associated with A\(\beta\). Increased concentrations of baseline plasma t-tau predicted structural basal forebrain
cholinergic system (BFCS) atrophy progression in older adults at risk of AD, independently of β-amyloid status and APOE genotype [57]. Elevated CSF NfL levels but not CSF T-tau, P-tau or Neurogranin are a risk factor for MCI in a community population, and they are independent of brain amyloid [58]. Rate of change of serum NfL was more associated with cortical thinning but less with amyloid-β deposition or glucose metabolism (assessed by positron emission tomography)[51]

Researches have shown that cerebrovascular processes are involved in the onset of the pathogenesis of AD, in which Cerebral amyloid angiopathy (CAA) is one of the factors. Accumulating evidence indicated that the intersections between CAA and AD has a crucial role to play in improving vascular function in the treatment of both diseases and indicated the next steps needed to identify therapies [59]. Cilostazol, a selective inhibitor of phosphodiesterase (PDE) III, promoted perivascular drainage of soluble fluorescent Aβ1-40 in Tg-SwDI mice [60]. However, the clinical trial of Cilostazol on the prevention of MCI is ongoing [61].

Conclusion
We observed that the deposition of Aβ resulted in the change of the biomarkers related to synaptic function, neuro-inflammation and neural injury, in which NfL and NG are majorly alternating. The relationship with tau protein is not consistent. Some research showed that alternation occurred before tau protein; but the relationship and time order of such biomarkers with tau protein
is not clear. The biomarkers experienced changes prior changes of the MRI findings and metabolism. The Aβ cascade could be the main hypothesis, however not all subjects converted to AD even with very high elevated Aβ. The interaction of biomarkers and the time order of the change require further research to identify the right subjects and right molecular target for precision medicine therapies.

Author Contributions
Conceptualization, Bin Zhou; Investigation, Bin Zhou; Original Draft Preparation, Bin Zhou; Writing – Review & Editing, Bin Zhou, Masanori Fukushima; Supervision, Masanori Fukushima.

Conflicts of Interest
The authors have no conflicts of Interests to be disclosed

Funding
The study has not received any funding.

Reference

1. Knopman, D.S. Lowering of Amyloid-Beta by β-Secretase Inhibitors - Some Informative Failures. N Engl J Med. 2019, 380, 1476-1478. doi: 10.1056/NEJMe1903193.
2. Egan, M.F.; Kost, J., Voss; T.; Mukai, Y.; Aisen, P.S. Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease. N Engl J Med. 2019, 380, 1408-1420. doi:10.1056/NEJMoa1812840
3. Henley, D.; Raghavan, N.; Sperling, R.; Aisen, P.S.; Raman, R.; Romano, G. Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer's Disease. N Engl J Med. 2019, 380, 1483-1485. doi: 10.1056/NEJMc1813435.
4. Timmers, M.; Streffer, J.R.; Russu, A.; Tominaga, Y., Shimizu, H. Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor
in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled study. *Alzheimers Res Ther.* 2018, 10, 85. doi: 10.1186/s13195-018-0415-6

5. Farrell, M. E.; Chen, X.; Rundle, M. M.; Chan, M. Y.; Wig, G. S.; Park, D. C. Regional amyloid accumulation and cognitive decline in initially amyloid-negative adults. *Neurology* 2018, 91(19).

6. Palmqvist, S.; Insel, P. S.; Stomrud, E.; Janelidze, S.; Zetterberg, H., Brix, B., Eichenlaub, U. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease. *EMBO Mol Med.* 2019, 11, e11170. doi: 10.15252/emmm.201911170.

7. Bischof, G. N.; Jacobs, H. I. L. Subthreshold amyloid and its biological and clinical meaning: Long way ahead. *Neurology* 2019, 93, 72-79. doi: 10.1212/WNL.0000000000007747.

8. Jack, C. R. Jr.; Holtzman, D. M. Biomarker modeling of Alzheimer's disease. *Neuron* 2013, 80, 1347-58. doi: 10.1016/j.neuron.2013.12.003.

9. Svenningsson, A. L.; Stomrud, E.; Insel, P. S.; Mattsson, N.; Palmqvist, S.; Hansson, O. β-amyloid pathology and hippocampal atrophy are independently associated with memory function in cognitively healthy elderly. *Sci Rep.* 2019, 9, 11180. doi: 10.1038/s41598-019-47638-y.

10. Soldan, A.; Pettigrew, C.; Fagan, A. M.; Schindler, S. E.; Moghekar, A.; Fowler, C. ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes. *Neurology* 2019, 92, e1567-e1579. doi: 10.1212/WNL.0000000000007248.

11. Altomare, D.; de Wilde, A.; Ossenkoppele, R.; Pelkmans, W.; Bouwman, F.; Groot, C. Applying the ATN scheme in a memory clinic population: The ABIDE project. *Neurology* 2019, 93, e1635-e1646. doi: 10.1212/WNL.000000000008361.

12. Zhou, B. Editorial: Prevention Strategies Targeting Different Preclinical Stages of Alzheimer's Disease. *Curr. Alzheimer Res.* 2015, 12, 504-6.

13. Sutphen, C. L.; McCue, L.; Herries, E. M.; Xiong, C.; Ladenson, J. H.; Holtzman, D. M. Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer's disease. *Alzheimers Dement.* 2018, 14, 869-879. doi: 10.1016/j.jalz.2018.01.012. Epub 2018 Mar 23. Lleó, A.; Alcolea, D.; Martínez-Lage, P.; Scheltens, P.; Parnetti, L.; Poirier, J. Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. *Alzheimers


14. Lleó, A.; Alcolea, D.; Martínez-Lage, P.; Scheltens, P.; Parnetti, L.; Poirier, J. Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. *Alzheimers Dement.* 2019, 15, 742-753. doi: 10.1016/j.jalz.2019.01.015.

15. Galasko, D.; Xiao, M.; Xu, D.; Smirnov, D.; Salmon, D.P.; Dewit, N. Alzheimer's Disease Neuroimaging Initiative (ADNI), Worley P. Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease. *Alzheimers Dement.* (N Y). 2019, 5, 871-882. doi: 10.1016/j.trci.2019.11.002.

16. Portelius, E.; Olsson, B.; Höglund, K.; Cullen, N.C.; Kvartsberg, H.; Andreasson, U. Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. *Acta Neuropathol.* 2018, 136, 363-376. doi: 10.1007/s00401-018-1851-x..

17. Höglund, K.; Schussler, N.; Kvartsberg, H.; Smailovic, U.; Brinkmalm, G.; Liman, V. Cerebrospinal fluid neurogranin in an inducible mouse model of neurodegeneration: A translatable marker of synaptic degeneration. *Neurobiol. Dis.* 2019, 134, 104645. doi: 10.1016/j.nbd.2019.104645.

18. Kirsebom, B.E.; Nordengen, K.; Selnes, P.; Waterloo, K.; Torsetnes, S.B.; Gisladöttir, B. Cerebrospinal fluid neurogranin/β-site APP-cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease. *Alzheimers Dement* (N Y). 2018, 4, 617-627. doi: 10.1016/j.trci.2018.10.003.

19. Schipke, C.G.; De Vos, A.; Fuentes, M.; Jacobs, D.; Vanmechelen, E.; Peters, O. Neurogranin and BACE1 in CSF as Potential Biomarkers Differentiating Depression with Cognitive Deficits from Early Alzheimer's Disease: A Pilot Study. *Dement. Geriatr. Cogn. Dis. Extra.* 2018, 8, 277-289. doi: 10.1159/000489847.

20. Beeri, M.S.; Haroutunian, V.; Schmeidler, J.; Sano, M.; Fam, P.; Kavanaugh, A. Synaptic protein deficits are associated with dementia irrespective of extreme old age. *Neurobiol Aging.* 2012, 33, 1125.e1-8. doi: 10.1016/j.neurobiolaging.2011.08.017.

21. Shimohama, S.; Kamiya, S.; Taniguchi, T.; Akagawa, K.; Kimura, J. Differential involvement of synaptic vesicle and presynaptic plasma membrane proteins in Alzheimer's disease. *Biochem. Biophys. Res. Commun.* 1997, 236, 239-42.

22. Shen, X.N.; Niu, L.D.; Wang, Y.J.; Cao, X.P.; Liu, Q.; Tan, L.; Zhang, C.; Yu, J.T. Inflammatory markers in Alzheimer's disease and mild cognitive
impairment: a meta-analysis and systematic review of 170 studies. *J. Neurol. Neurosurg. Psychiatry.* **2019**, 90, 590-598. doi: 10.1136/jnnp-2018-319148.

23. Singh-Bains, M.K.; Linke, V.; Austria, M.D.R.; Tan, A.Y.S.; Scotter, E.L.; Mehrabi, N.F. Altered microglia and neurovasculature in the Alzheimer's disease cerebellum. *Neurobiol. Dis.* **2019**, 132, 104589.

24. Ashton, N.J.; Suárez-Calvet, M.; Heslegrave, A.; Hye, A.; Razquin, C.; Pastor, P. Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers. *Alzheimers Res. Ther.* **2019**, 11, 94. doi: 10.1186/s13195-019-0545-5.

25. Olsson, B.; Portelius, E.; Cullen, N.C.; Sandelius, Å.; Zetterberg, H.; Andreasson, U. Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders. *JAMA Neurol.* **2019**, 76, 318-325. doi: 10.1001/jamaneurol.2018.3746.

26. Illán-Gala, I.; Alcolea, D.; Montal, V.; Dols-Icardo, O.; Muñoz, L.; de Luna, N. CSF sAPPβ, YKL-40, and NFL along the ALS-FTD spectrum. *Neurology.* **2018**, 91, e1619-e1628. doi: 10.1212/WNL.0000000000006383.

27. Abu-Rumeileh, S.; Mometto, N.; Bartoletti-Stella, A.; Polischi, B.; Oppi, F.; Poda, R. Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study. *J. Alzheimers Dis.* **2018**, 66, 551-563. doi: 10.3233/JAD-180409.

28. Vijverberg, E.G.; Dols, A.; Krudop, W.A.; Del Campo Milan, M.; Kerssens, C.J.; Gossink, F. Cerebrospinal fluid biomarker examination as a tool to discriminate behavioral variant frontotemporal dementia from primary psychiatric disorders. *Alzheimers Dement.* (Amst.) **2017**, 7, 99-106. doi: 10.1016/j.jdadm.2017.01.009.

29. van der Ende, E.L.; Meeter, L.H.; Poos, J.M.; Panman, J.L.; Jiskoot, L.C.; Dopper, E.G.P. Genetic Frontotemporal dementia Initiative (GENFI). Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. *Lancet Neurol.* **2019**, 18, 1103-1111. doi: 10.1016/S1474-4422(19)30354-0.

30. Bridel, C.; van Wieringen, W.N.; Zetterberg, H.; Tijms, B.M.; Teunissen, C.E. Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. *JAMA Neurol.* **2019**, Jun 17. doi: 10.1001/jamaneurol.2019.1534. [Epub ahead of print]

31. Mavroudis, I.A.; Petridis, F.; Chatzikonstantinou, S.; Karantali, E.; Kazis, D. A
meta-analysis on the levels of VILIP-1 in the CSF of Alzheimer's disease compared to normal controls and other neurodegenerative conditions. Aging Clin. Exp. Res. 2020, Jan 14. doi: 10.1007/s40520-019-01458-2.

32. Johansson, L.; Sacuiu, S.; Kern, S.; Guo, X.; Zetterberg, H.; Blennow, K. Longstanding psychological stress in relation to biomarkers of neuronal dysfunction in cerebrospinal fluid: a 25-year follow-up study in women. Neurobiol. Aging. 2019, 80, 111-115. doi: 10.1016/j.neurobiolaging.2019.02.013.

33. Dani, M.; Wood, M.; Mizoguchi, R.; Fan, Z.; Walker, Z.; Morgan, R.; Hinz, R. Edison P1Microglial activation correlates in vivo with both tau and amyloid in Alzheimer's disease. Brain 2018, 141, 2740-2754. doi: 10.1093/brain/awy188.

34. Honer, W.G.; Ramos-Miguel, A.; Alamri, J.; Sawada, K.; Barr, A.M.; Schneider, J.A. The synaptic pathology of cognitive life. Dialogues Clin Neurosci. 2019, 21, 271-279. doi: 10.31887/DCNS.2019.21.3.

35. Parbo, P.; Ismail, R.; Sommerauer, M.; Stockholm, M.G.; Hansen, A.K.; Hansen, K.V. Does inflammation precede tau aggregation in early Alzheimer's disease? A PET study. Neurobiol Dis. 2018, 117, 211-216. doi: 10.1016/j.nbd.2018.06.004.

36. Bos, I.; Vos, S.; Verhey, F.; Scheltens, P.; Teunissen, C.; Engelborghs, S. Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. Alzheimers Dement. 2019, 15, 644-654. doi: 10.1016/j.jalz.2019.01.004.

37. Melah, K.E.; Lu, S.Y.; Hoscheidt, S.M.; Alexander, A.L.; Adluru, N.; Destiche, D.J. Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease. J. Alzheimers Dis. 2016, 50, 873-86. doi: 10.3233/JAD-150897.

38. Jin, M.; Cao, L.; Dai, Y.P. Role of Neurofilament Light Chain as a Potential Biomarker for Alzheimer's Disease: A Correlative Meta-Analysis. Front Aging Neurosci. 2019, 11, 254. doi: 10.3389/fnagi.2019.00254.

39. Kvartsberg, H.; Lashley, T.; Murray, C.E.; Brinkmalm, G.; Cullen, N.C.; Höglund, K. The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer's disease. Acta Neuropathol. 2019, 137, 89-102. doi: 10.1007/s00401-018-1910-3.

40. Mielke, M.M.; Syrjanen, J.A.; Blennow, K.; Zetterberg, H.; Skoog, I.; Vemuri, P. Comparison of variables associated with cerebrospinal fluid neurofilament,
total-tau, and neurogranin. *Alzheimers Dement.* 2019, 15, 1437-1447. doi: 10.1016/j.jalz.2019.07.009.

41. Das, S.R.; Xie, L.; Wisse, L.E.M.; Ittyerah, R.; Tustison, N.J.; Dickerson, B.C. Alzheimer's Disease Neuroimaging Initiative. Longitudinal and cross-sectional structural magnetic resonance imaging correlates of AV-1451 uptake. *Neurobiol. Aging.* 2018, 66, 49-58. doi: 10.1016/j.neurobiolaging.2018.01.024.

42. Pascoal, T.A.; Mathotaarachchi, S.; Kang, M.S.; Mohaddes, S.; Shin, M.; Park, A.Y. Aβ-induced vulnerability propagates via the brain's default mode network. *Nat. Commun.* 2019, 10, 2353. doi: 10.1038/s41467-019-10217-w.

43. Guerini, F.R.; Agliardi, C.; Sironi, M.; Arosio, B.; Calabrese, E.; Zanzottera, M. Possible association between SNAP-25 single nucleotide polymorphisms and alterations of categorical fluency and functional MRI parameters in Alzheimer's disease. *J. Alzheimers Dis.* 2014, 42, 1015-28. doi: 10.3233/JAD-140057.

44. Zhang, H.; Therriault, J.; Kang, M.S.; Ng, K.P.; Pascoal, T.A.; Rosa-Neto, P. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease. *Alzheimers Res. Ther.* 2018, 10, 80. doi: 10.1186/s13195-018-0407-6.

45. Tarawneh, R.; D'Angelo, G.; Crimmins, D.; Herries, E.; Griest, T.; Fagan, A.M. Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease. *JAMA Neurol.* 2016, 73, 561-71. doi: 10.1001/jamaneurol.2016.0086.

46. Kirsebom, B.E.; Nordengen, K.; Selnes, P.; Waterloo, K.; Torsetnes, S.B.; Gisladóttir, B. Cerebrospinal fluid neurogranin/β-site APP-cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease. *Alzheimers Dement.* (N Y). 2018, 4, 617-627. doi: 10.1016/j.trci.2018.10.003.

47. Kim, W.H.; Racine, A.M.; Adluru, N.; Hwang, S.J.; BlennoW, K.; Zetterberg, H. Cerebrospinal fluid biomarkers of neurofibrillary tangles and synaptic dysfunction are associated with longitudinal decline in white matter connectivity: A multi-resolution graph analysis. *Neuroimage Clin.* 2019, 21, 101586. doi: 10.1016/j.nicl.2018.10.024.

48. Schaeverbeke, J.; Gille, B.; Adamczuk, K.; Vanderstichele, H.; Chassaing, E.; Bruffaerts, R. Cerebrospinal fluid levels of synaptic and neuronal integrity correlate with gray matter volume and amyloid load in the precuneus of cognitively intact older adults. *J. Neurochem.* 2019, 149, 139-157. doi:
57. Cavedo, E.; Lista, S.; Houot, M.; Vergallo, A.; Grothe, M.J.; Teipel, S. INSIGHT-preAD Study Group and the Alzheimer Precision Medicine Initiative.
Plasma tau correlates with basal forebrain atrophy rates in people at risk for Alzheimer disease. *Neurology* 2019, pii: 10.1212/WNL.0000000000008696. doi: 10.1212/WNL.0000000000008696. [Epub ahead of print]

58. Kern, S.; Syrjanen, J.A.; Blennow, K.; Zetterberg, H.; Skoog, I.; Waern, M. Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment. *JAMA Neurol.* 2019, 76, 187-193. doi: 10.1001/jamaneurol.2018.3459.

59. Greenberg, S.M.; Bacskai, B.J.; Hernandez-Guillamon, M.; Pruzin, J.; Sperling, R.; van Veluw, S.J. Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways. *Nat. Rev. Neurol.* 2020, 16, 30-42. doi: 10.1038/s41582-019-0281-2.

60. Maki, T.; Okamoto, Y.; Carare, R.O.; Hase, Y.; Hattori, Y.; Hawkes, C.A. Phosphodiesterase III inhibitor promotes drainage of cerebrovascular β-amyloid. *Ann. Clin. Transl. Neurol.* 2014, 1, 519-33. doi: 10.1002/acn3.79.

61. Saito, S.; Kojima, S.; Oishi, N.; Kakuta, R.; Maki, T.; Yasuno, F. A multicenter, randomized, placebo-controlled trial for cilostazol in patients with mild cognitive impairment: The COMCID study protocol. *Alzheimers Dement* (NY). 2016, 2, 250-257. doi: 10.1016/j.trci.2016.10.001.
Figure 1: Hypothesis of AD pathogenesis

Vascular factors
- hFABp, CAA, CBF

CSF A\(\beta\)
CSF Tau
PET A\(\beta\)

CGM, FDG-PET

Neuro-inflammation
Synaptic dysfunction
Neuronal injury
Others

Brain Structural atrophy

Neurodegeneration

AD
Figure 2 Interaction among the proteins

Blue: association; Green: Negative association;